Balchem Corporation Signs Definitive Agreement to Acquire Kappa Bioscience AS

Posted: June 14, 2022

Balchem is pleased to announce the acquisition of market-leading vitamin K2 producer, Kappa Bioscience. This exciting deal aligns well with our strategic focus and our vision of making the world a healthier place. Kappa Bioscience is dedicated to developing superior quality health solutions around vitamin K2 to improve the quality of life.

Kappa Bioscience is the only company offering a patented, 99.7% all-trans vitamin K2 MK-7, identical to the K2 molecule found in nature and fully bioactive. Kappa’s thought leadership in the health & well-being market is driven by the quest-for-truth, rooted in science & commercial expertise and Norwegian heritage, demonstrated by its patented organic synthesis and microencapsulated K2VITAL® DELTA. 

Vitamin K2 is a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. Kappa’s K2VITAL® branded vitamin K2 is the leading synthetic vitamin K2 and is backed by strong intellectual property and a deep clinical research portfolio.

To learn more about Kappa and their product offerings, click here: K2 Science – development of vitamin K2 | Kappa Bioscience | Kappa